Stem cell technologies in regenerative medicine

Expert Opinion on Biological Therapy

Volumn 2, Issue 7, 2002, Pages 771-773

  Jain, Kewal K ^a  

^a JAIN PHARMABIOTECH   (Switzerland)

Author keywords

Biomedical ethics; Cell therapy; Drug discovery; Embryonic stem cells; Regenerative medicine; Stem cells

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; CONFERENCE PAPER; EMBRYO CELL; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH ECONOMICS; LIVER FAILURE; MEDICAL ETHICS; MEDICAL SOCIETY; REGULATORY MECHANISM; STEM CELL TRANSPLANTATION;

ANIMALS; DIABETES MELLITUS; DRUG DESIGN; HUMANS; LIVER FAILURE; NEURODEGENERATIVE DISEASES; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 0036794505     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.7.771     Document Type: Conference Paper

References (6)

1. Jain KK: Cell Therapy: Technologies, Markets and Companies (4th edn). Jain PharmaBiotech Publications, UK (2002):1-340.
2. Dohrmann C, Gruss P, Lemaire L: Pax genes and the differentiation of hormone-producing endocrine cells in the pancreas. Mech. Dev. (2000) 92:47-54.
3. Strom TB, Field LJ, Ruediger M: Allogeneic stem cells, clinical transplantation, and the origins of regenerative medicine. Transplant Proc. (2001) 33:3044-3049.
4. Hugnot JP, Pilcher H, Rashid-Doubell F et al.: Regulation of glial differentiation of MHP36 neural multipotent cell line. Neuroreport (2001) 12:2237-2241.
5. Bishop AE, Buttery LD, Polak JM: Embryonic stem cells. J. Pathol. (2002) 197:424-429.
6. Jain KK: Ethical and regulatory aspects of embryonic stem cell research. Expert Opin. Biol. Ther. (2002) (Submitted).